Most recent update: Thursday, January 23, 2020 - 09:45

Bariatric News - Cookies & privacy policy

You are here

diabetes

Consumed soybean oil causes genetic changes in the brain

A study by researchers at UC Riverside shows that soybean oil not only leads to obesity and diabetes, but could also affect neurological conditions like autism, Alzheimer's disease, anxiety and depression. Used for fast food frying, added to packaged foods, and fed to livestock, soybean oil is by far the most widely produced and consumed edible oil in the US (Figure 1), according to the U.S. Department of Agriculture. In all likelihood, it is not healthy for humans.

Obesity, heart disease, and diabetes may be communicable diseases

Non-communicable diseases such as heart disease, cancer and lung disease are the most common causes of death, accounting for 70 percent of deaths worldwide, and are considered ‘non-communicable’ because they are thought to be caused by a combination of genetic, lifestyle and environmental factors and cannot be transmitted between people.

Cleveland Clinic calculator estimates ten-year risk of T2DM complications

A new risk calculator developed by Cleveland Clinic researchers can show patients who are struggling with type 2 diabetes and obesity their risks of developing major health complications over the next ten years depending on which course of treatment they choose. The research was presented as one of the Top 10 studies at the ObesityWeek 2019 international conference in Las Vegas.

Patients with obesity have better outcomes than severe patients

A study has found that bariatric surgery improves or resolves diabetes, reduces heart attacks and strokes and produces significant weight loss in patients who are 50 to 70lbs overweight (BMI<35) and that these patients are even more likely to reach a healthy weight, have a higher quality of life and improve or resolve their type 2 diabetes. The findings were presented today by researchers from the University of Michigan (U-M) at the 36th American Society for Metabolic and Bariatric Surgery (ASMBS) Annual Meeting at ObesityWeek 2019.

Diabetes rates nearly double for Japanese-Americans

Japanese-American adults who are not obese have a much higher prevalence of diabetes than non-obese non-Hispanic white Americans (8.0% vs. 4.5%), according to researchers at the University of Victoria, University of Toronto, and University at Albany, SUNY.

Gene therapy reduced obesity and reversed type 2 diabetes in mice

Researchers from Hanyang University, Seoul, in South Korea, have successfully developed a gene therapy that specifically reduced fat tissue and reversed obesity-related metabolic disease in obese mice. To overcome the side effects of current anti-obesity drugs, researcher Dr Jee Young Chung and colleagues developed a specific gene silencing therapy against a fatty acid metabolism gene, Fabp4.

Whole body vibration can reduce inflammation in diabetes

Whole body vibration appears to improve how well our body uses glucose as an energy source and adjust our microbiome and immune cells to deter inflammation, according to researchers from Medical College of Georgia and Dental College of Georgia at Augusta University. For the first time, they have described how regular use of whole body vibration can create this healthier mix by yielding a greater percentage of macrophages - cells that can both promote or prevent inflammation - that suppress rather than promote.

New US diabetes cases fall as obesity rises

The number of new diabetes cases among US adults keeps falling, even as obesity rates climb, according to research led by Dr Stephen Benoit of the Centers for Disease Control and Prevention. The new federal data revealed the number of new diabetes diagnoses fell to about 1.3 million in 2017, down from 1.7 million in 2009, a decline that has been going on for close to a decade. However, health officials are not celebrating.

ZGN-1061 trial shows clinically significant 1.1% reduction of A1C

Zafgen has announced positive data for the second cohort of its Phase 2 clinical trial of ZGN-1061, designed to evaluate efficacy and safety in patients with type 2 diabetes and the likely therapeutic dose range of ZGN-1061 up to 1.8mg. The clinical trial met all of its primary objectives at the 1.8mg dose, which included glycaemic control or change in A1C, and safety and tolerability.

Very low-calorie diets trialled by NHS to tackle diabetes

Hundreds of thousands of people in the England will receive NHS help to battle obesity and type 2 diabetes in a programme that will not only improve the health of patients but also save the NHS money that can be reinvested in frontline care. Currently, the health service in England spends around 10 percent of its budget on treating diabetes.

Subscribe to RSS - diabetes